Blueprint Medicines Corp (FRA:2L9)
€ 97.7 -2.35 (-2.35%) Market Cap: 6.13 Bil Enterprise Value: 5.83 Bil PE Ratio: 0 PB Ratio: 21.19 GF Score: 68/100

Blueprint Medicines Corp Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress Transcript

Jun 17, 2019 / 12:30PM GMT
Release Date Price: €85.69 (+8.66%)
Operator

Good day, ladies and gentlemen, and welcome to the Blueprint Medicines Corp. conference call. (Operator Instructions) I would now like to introduce your host for this conference call, Ms. Kristin Hodous. You may begin.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone, and thank you for joining us today for an update on our avapritinib development program, including new clinical data in advanced systemic mastocytosis that were presented on Saturday at the 24th Congress of the European Hematology Association or EHA.

You can access the press release for the avapritinib data as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com. With me today with prepared remarks are Jeff Albers, our Chief Executive Officer; and Dr. Andy Boral, our Chief Medical Officer.

Before we get started, I would like to remind everyone that statements we make

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot